Next Article in Journal
Seed Coating Increases Seed Moisture Uptake and Restricts Embryonic Oxygen Availability in Germinating Cereal Seeds
Previous Article in Journal
Characterisation of Arctic Bacterial Communities in the Air above Svalbard
Article Menu

Export Article

Open AccessArticle
Biology 2017, 6(2), 30; doi:10.3390/biology6020030

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin

1
Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
2
Safety and Health Organization, Chiba University, 1-33 Yayoicho, Inage-ku, Chiba 263-8522, Japan
3
Department of Molecular Virology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
Current address: Japan Community Health Care Organization Funabashi Central Hospital, 6-13-10 Kaijin, Funabashi 273-8556, Japan.
*
Author to whom correspondence should be addressed.
Academic Editor: Chris O’Callaghan
Received: 1 March 2017 / Revised: 4 May 2017 / Accepted: 6 May 2017 / Published: 9 May 2017
View Full-Text   |   Download PDF [636 KB, uploaded 22 May 2017]   |  

Abstract

The aim of this study was to characterize the treatment response and tolerability of sofosbuvir plus ribavirin therapies in Japanese patients infected with hepatitis C virus (HCV) genotype (GT)-2. This retrospective study analyzed 114 Japanese HCV GT-2 patients treated for 12 weeks with 400 mg of sofosbuvir plus weight-based ribavirin daily. This treatment led to higher sustained virologic response at 12-weeks post-treatment (SVR12) rates in both treatment-naïve and treatment-experienced patients. The efficacy of this treatment in compensated cirrhotics was the same as that in patients with chronic hepatitis. HCV GT-2a infection and lower estimated glomerular filtration rates (eGFR) tended to be associated with SVR12. Of 114 patients, 113 completed the combination of sofosbuvir plus ribavirin for 12 weeks. Seven patients without SVR12 did not have HCV NS5B-S282 mutations. The overall SVR12 rate was 90.4% (103 of 114). More effective therapeutic options with less adverse events are desired to achieve higher SVR rates in HCV GT-2 Japanese patients. View Full-Text
Keywords: genotype 2; hepatitis C virus; ribavirin; sofosbuvir; treatment-experienced genotype 2; hepatitis C virus; ribavirin; sofosbuvir; treatment-experienced
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Kanda, T.; Nakamura, M.; Yasui, S.; Haga, Y.; Tawada, A.; Suzuki, E.; Ooka, Y.; Takahashi, K.; Sasaki, R.; Wu, S.; Nakamoto, S.; Arai, M.; Imazeki, F.; Yokosuka, O. Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. Biology 2017, 6, 30.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biology EISSN 2079-7737 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top